- Home
- WFC vs NVO Comparison
WFC vs NVO Comparison
Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | NVO |
|---|---|---|
| Founded | 1852 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6B | 269.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WFC | NVO |
|---|---|---|
| Price | $86.62 | $49.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 10 |
| Target Price | ★ $97.37 | $54.25 |
| AVG Volume (30 Days) | 16.9M | ★ 26.4M |
| Earning Date | 01-14-2026 | 02-04-2026 |
| Dividend Yield | 2.07% | ★ 2.48% |
| EPS Growth | ★ 16.57 | 1.77 |
| EPS | ★ 6.26 | 3.62 |
| Revenue | ★ $80,041,000,000.00 | $48,588,245,669.00 |
| Revenue This Year | $11.53 | $1.02 |
| Revenue Next Year | $4.57 | $6.81 |
| P/E Ratio | $13.89 | ★ $13.61 |
| Revenue Growth | 2.67 | ★ 6.43 |
| 52 Week Low | $58.42 | $43.08 |
| 52 Week High | $97.76 | $93.80 |
Technical Indicators
Market Signals| Indicator | WFC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 41.95 |
| Support Level | $89.00 | $48.08 |
| Resistance Level | $95.09 | $50.07 |
| Average True Range (ATR) | 2.93 | 2.09 |
| MACD | -0.40 | -0.98 |
| Stochastic Oscillator | 18.90 | 32.06 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $2.1 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US market.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.